Nevro Corp. Stock
Your prediction
Pros and Cons of Nevro Corp. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Nevro Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nevro Corp. | - | - | - | - | - | - | - |
| Lantheus Holdings Inc | 0.920% | -3.947% | -9.877% | 39.269% | 53.147% | 9.802% | - |
| Natera Inc | 1.750% | 0.473% | -1.599% | 88.629% | 18.731% | 446.495% | 147.513% |
| Orasure Tech | 1.180% | 4.268% | -11.856% | 18.750% | 66.019% | -18.182% | -63.648% |
Comments
Nevro Corp. (NYSE: NVRO) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $5.85 price target on the stock, down previously from $6.00.
Show more
Ratings data for NVRO provided by MarketBeat
Nevro Corp. (NYSE: NVRO) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $4.00 price target on the stock, down previously from $9.00.
Show more
Ratings data for NVRO provided by MarketBeat
Nevro Corp. (NYSE: NVRO) had its price target lowered by analysts at Piper Sandler from $7.00 to $6.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for NVRO provided by MarketBeat
News
Globus Medical Q1 Earnings Call Highlights
Globus Medical (NYSE:GMED) reported a strong start to 2026, with first-quarter revenue and earnings rising sharply as the company cited continued momentum in U.S. spine, margin expansion and
